Early Alzheimer's trials: new developments.

Suppr

超能文献

作者信息

Vellas B, Aisen P S

出版信息

J Nutr Health Aging. 2010 Apr;14(4):293. doi: 10.1007/s12603-010-0064-3.

DOI:10.1007/s12603-010-0064-3

PMID:20305997

Abstract

摘要

相似文献

Early Alzheimer's trials: new developments.

J Nutr Health Aging. 2010 Apr;14(4):293. doi: 10.1007/s12603-010-0064-3.

Antibody drugs for Alzheimer's show glimmers of promise.

Nature. 2015 Jul 30;523(7562):509-10. doi: 10.1038/nature.2015.18031.

The amyloid hypothesis for Alzheimer's disease: a critical reappraisal.

J Neurochem. 2009 Aug;110(4):1129-34. doi: 10.1111/j.1471-4159.2009.06181.x. Epub 2009 May 18.

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics.

Nat Rev Drug Discov. 2011 Aug 19;10(9):698-712. doi: 10.1038/nrd3505.

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Brain. 2006 Nov;129(Pt 11):2856-66. doi: 10.1093/brain/awl178. Epub 2006 Jul 19.

NEUROSCIENCE. Alzheimer's amyloid theory gets modest boost.

Science. 2015 Jul 31;349(6247):464. doi: 10.1126/science.349.6247.464.

Peptides isolated from animal venom as a platform for new therapeutics for the treatment of Alzheimer's disease.

Neuropeptides. 2018 Feb;67:79-86. doi: 10.1016/j.npep.2017.11.010. Epub 2017 Nov 28.

Alzheimer's disease: beta-amyloid hypothesis strengthened!

Trends Neurosci. 2001 Apr;24(4):199. doi: 10.1016/s0166-2236(00)01799-9.

Why are drug trials in Alzheimer's disease failing?

Lancet. 2010 Oct 30;376(9751):1466. doi: 10.1016/S0140-6736(10)61994-0.

Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease.

Curr Opin Chem Biol. 1997 Aug;1(2):260-7. doi: 10.1016/s1367-5931(97)80018-x.

引用本文的文献

Vitamin D supplements: a novel therapeutic approach for Alzheimer patients.

Front Pharmacol. 2014 Jan 28;5:6. doi: 10.3389/fphar.2014.00006. eCollection 2014.

Brain investigation and brain conceptualization.

Funct Neurol. 2013 Jul-Sep;28(3):175-90.

Possibility of a new anti-alzheimer's disease pharmaceutical composition combining memantine and vitamin D.

Drugs Aging. 2012 Feb 1;29(2):81-91. doi: 10.2165/11597550-000000000-00000.

Advances in tau-based drug discovery.

Expert Opin Drug Discov. 2011 Aug 1;6(8):797-810. doi: 10.1517/17460441.2011.586690.

本文引用的文献

Study design considerations: conducting global clinical trials in early Alzheimer's disease.

J Nutr Health Aging. 2010 Apr;14(4):312-4. doi: 10.1007/s12603-010-0071-4.

Dose ranging for trials through biomarkers of drug effects.

J Nutr Health Aging. 2010 Apr;14(4):310-1. doi: 10.1007/s12603-010-0070-5.

Seeing with new eyes: finding a path to early intervention trials in Alzheimer's disease.

J Nutr Health Aging. 2010 Apr;14(4):306-9. doi: 10.1007/s12603-010-0069-y.

Clinical trials for early (pre-dementia) Alzheimer's disease: a case for mild cognitive impairment.

J Nutr Health Aging. 2010 Apr;14(4):304-5. doi: 10.1007/s12603-010-0068-z.

Evolving early (pre-dementia) Alzheimer's disease trials: suit the outcomes to the population and study design.

J Nutr Health Aging. 2010 Apr;14(4):299-302. doi: 10.1007/s12603-010-0067-0.

The potential and limits for clinical trials for early Alzheimer's disease and some recommendations.

J Nutr Health Aging. 2010 Apr;14(4):295-8. doi: 10.1007/s12603-010-0066-1.

Pre-dementia Alzheimer's trials: overview.

J Nutr Health Aging. 2010 Apr;14(4):294. doi: 10.1007/s12603-010-0065-2.

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Lancet Neurol. 2010 Jan;9(1):119-28. doi: 10.1016/S1474-4422(09)70299-6.

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

Ann Neurol. 2006 Mar;59(3):512-9. doi: 10.1002/ana.20730.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Early Alzheimer's trials: new developments.

J Nutr Health Aging. 2010 Apr;14(4):293. doi: 10.1007/s12603-010-0064-3.

Antibody drugs for Alzheimer's show glimmers of promise.

Nature. 2015 Jul 30;523(7562):509-10. doi: 10.1038/nature.2015.18031.

The amyloid hypothesis for Alzheimer's disease: a critical reappraisal.

J Neurochem. 2009 Aug;110(4):1129-34. doi: 10.1111/j.1471-4159.2009.06181.x. Epub 2009 May 18.

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics.

Nat Rev Drug Discov. 2011 Aug 19;10(9):698-712. doi: 10.1038/nrd3505.

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Brain. 2006 Nov;129(Pt 11):2856-66. doi: 10.1093/brain/awl178. Epub 2006 Jul 19.

NEUROSCIENCE. Alzheimer's amyloid theory gets modest boost.

Science. 2015 Jul 31;349(6247):464. doi: 10.1126/science.349.6247.464.

Peptides isolated from animal venom as a platform for new therapeutics for the treatment of Alzheimer's disease.

Neuropeptides. 2018 Feb;67:79-86. doi: 10.1016/j.npep.2017.11.010. Epub 2017 Nov 28.

Alzheimer's disease: beta-amyloid hypothesis strengthened!

Trends Neurosci. 2001 Apr;24(4):199. doi: 10.1016/s0166-2236(00)01799-9.

Why are drug trials in Alzheimer's disease failing?

Lancet. 2010 Oct 30;376(9751):1466. doi: 10.1016/S0140-6736(10)61994-0.

Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease.

Curr Opin Chem Biol. 1997 Aug;1(2):260-7. doi: 10.1016/s1367-5931(97)80018-x.

引用本文的文献

Vitamin D supplements: a novel therapeutic approach for Alzheimer patients.

Front Pharmacol. 2014 Jan 28;5:6. doi: 10.3389/fphar.2014.00006. eCollection 2014.

Brain investigation and brain conceptualization.

Funct Neurol. 2013 Jul-Sep;28(3):175-90.

Possibility of a new anti-alzheimer's disease pharmaceutical composition combining memantine and vitamin D.

Drugs Aging. 2012 Feb 1;29(2):81-91. doi: 10.2165/11597550-000000000-00000.

Advances in tau-based drug discovery.

Expert Opin Drug Discov. 2011 Aug 1;6(8):797-810. doi: 10.1517/17460441.2011.586690.

本文引用的文献

Study design considerations: conducting global clinical trials in early Alzheimer's disease.

J Nutr Health Aging. 2010 Apr;14(4):312-4. doi: 10.1007/s12603-010-0071-4.

Dose ranging for trials through biomarkers of drug effects.

J Nutr Health Aging. 2010 Apr;14(4):310-1. doi: 10.1007/s12603-010-0070-5.

Seeing with new eyes: finding a path to early intervention trials in Alzheimer's disease.

J Nutr Health Aging. 2010 Apr;14(4):306-9. doi: 10.1007/s12603-010-0069-y.

Clinical trials for early (pre-dementia) Alzheimer's disease: a case for mild cognitive impairment.

J Nutr Health Aging. 2010 Apr;14(4):304-5. doi: 10.1007/s12603-010-0068-z.

Evolving early (pre-dementia) Alzheimer's disease trials: suit the outcomes to the population and study design.

J Nutr Health Aging. 2010 Apr;14(4):299-302. doi: 10.1007/s12603-010-0067-0.

The potential and limits for clinical trials for early Alzheimer's disease and some recommendations.

J Nutr Health Aging. 2010 Apr;14(4):295-8. doi: 10.1007/s12603-010-0066-1.

Pre-dementia Alzheimer's trials: overview.

J Nutr Health Aging. 2010 Apr;14(4):294. doi: 10.1007/s12603-010-0065-2.

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Lancet Neurol. 2010 Jan;9(1):119-28. doi: 10.1016/S1474-4422(09)70299-6.

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

Ann Neurol. 2006 Mar;59(3):512-9. doi: 10.1002/ana.20730.